APOGEE THERAPEUTICS INC (APGE) — insider trading
Health Care · NASDAQ
APOGEE THERAPEUTICS INC (APGE) has 22 reported SEC Form 4 insider transactions in our data, including 11 open-market sales among the most recent 22 (latest 2026-07-10).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Bona fide gift | 75,046 | $0.00 | $0 | Form 4 |
| 2026-07-08 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 20,000 | $133.63 | $2.67M | Form 4 |
| 2026-07-01 | Dambkowski Carl | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 4,125 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Dambkowski Carl | Officer (Chief Medical Officer) | Open-market sale | 5,500 | $132.74 | $730.1K | Form 4 |
| 2026-07-01 | Dambkowski Carl | Officer (Chief Medical Officer) | Option exercise / conversion | 4,125 | $22.86 | $94.3K | Form 4 |
| 2026-06-22 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 80,000 | $132.54 | $10.60M | Form 4 |
| 2026-06-22 | Dambkowski Carl | Officer (Chief Medical Officer) | Open-market sale | 26,400 | $132.60 | $3.50M | Form 4 |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 614 | $86.89 | $53.4K | Form 4 |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 2,305 | $86.27 | $198.9K | Form 4 |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 1,577 | $85.19 | $134.3K | Form 4 |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 1,080 | $84.18 | $90.9K | Form 4 |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 7,654 | $82.78 | $633.6K | Form 4 |
| 2026-06-10 | HENDERSON MICHAEL THOMAS | Director, Officer (Chief Executive Officer) | Open-market sale | 6,770 | $82.21 | $556.6K | Form 4 |
| 2026-06-09 | Bollinger Lisa | Director | Grant / award / vesting (derivative) | 7,657 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Fox Jennifer A. | Director | Grant / award / vesting (derivative) | 7,657 | $0.00 | $0 | Form 4 |
| 2026-06-09 | JONES WILLIAM A JR | Director | Grant / award / vesting (derivative) | 7,657 | $0.00 | $0 | Form 4 |
| 2026-06-09 | McKenna Mark C. | Director | Grant / award / vesting (derivative) | 7,657 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Shah Nimish P | Director | Grant / award / vesting (derivative) | 7,657 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Fairmount Funds Management LLC; Kiselak Tomas | Director | Grant / award / vesting (derivative) | 7,657 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Dambkowski Carl | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 4,125 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Dambkowski Carl | Officer (Chief Medical Officer) | Open-market sale | 5,500 | $78.71 | $432.9K | Form 4 |
| 2026-06-03 | Dambkowski Carl | Officer (Chief Medical Officer) | Option exercise / conversion | 4,125 | $22.86 | $94.3K | Form 4 |
Ask the chat about APGE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: APOGEE THERAPEUTICS INC (APGE).
Last updated 2026-07-10 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.